Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 20/20 | 0.85 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.58 |
| ▸ | CIT | O14578 | 3/20 | 0.58 |
| ▸ | MYLK2 | Q9H1R3 | 3/20 | 0.58 |
| ▸ | BMP2K | Q9NSY1 | 3/20 | 0.58 |
| ▸ | PRKCB | P05771 | 1/20 | 0.58 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.58 |
| ▸ | GAK | O14976 | 2/20 | 0.55 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30578944 | 0.92 | AAK1 (1.00) | AAK1MKNK1CITMYLK2BMP2K | |
| SCHEMBL30059525 | 0.92 | AAK1 (1.00) | AAK1MKNK1CITMYLK2BMP2K | |
| SCHEMBL19901243 | 0.92 | AAK1 (1.00) | AAK1MKNK1CITMYLK2BMP2K | |
| SCHEMBL30059558 | 0.92 | AAK1 (1.00) | AAK1MKNK1CITMYLK2BMP2K | |
| SCHEMBL17155656 | 0.92 | AAK1 (1.00) | AAK1MKNK1CITMYLK2BMP2K | |
| SCHEMBL29400172 | 0.92 | AAK1 (1.00) | AAK1MKNK1CITMYLK2BMP2K | |
| SCHEMBL17155448 | 0.92 | AAK1 (1.00) | AAK1MKNK1CITMYLK2BMP2K | |
| SCHEMBL17143553 | 0.89 | AAK1 (0.85) | AAK1MKNK1CITMYLK2BMP2K | |
| SCHEMBL17143704 | 0.86 | AAK1 (0.85) | AAK1MKNK1CITMYLK2BMP2K | |
| SCHEMBL19901234 | 0.85 | AAK1 (1.00) | AAK1MKNK1CITMYLK2BMP2K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126351-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-19 | — | — | EP | claimed |
| US-9902722-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | claimed |
| US-20170183340-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-29 | — | — | US | claimed |
| EP-3126351-A1 | BIARYL KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-02-08 | — | — | EP | claimed |
| WO-2015153720-A1 | BIARYL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | claimed |
| WO-2023200892-A1 | COMPOUNDS AND METHODS FOR TREATING SPASTICITY | LEXICON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230330074-A1 | COMPOUNDS AND METHODS FOR TREATING SPASTICITY | LEXICON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11730723-B2 | Compounds and methods for treating viral infections | LEXICON PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4138829-A1 | AAK1 INHIBITORS FOR USE IN TREATING VIRAL INFECTIONS | Lexicon Pharmaceuticals, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220054464-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | OXFORD FINANCE LLC | 2022-02-24 | — | — | US | disclosed |
| WO-2021216441-A1 | AAK1 INHIBITORS FOR USE IN TREATING VIRAL INFECTIONS | LEXICON PHARMACEUTICALS, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20210277001-A1 | BIARYL KINASE INHIBITORS | Cosmic Pet LLC | 2021-09-09 | — | — | US | disclosed |
| US-20180346440-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-12-06 | — | — | US | disclosed |
| EP-3126351-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-3356340-A1 | BIARYL KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180134704-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-17 | — | — | US | disclosed |
| US-9902722-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170183340-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-29 | — | — | US | disclosed |
| EP-3126351-A1 | BIARYL KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015153720-A1 | BIARYL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134704-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | AAK1 1/4885MKNK1 37/4885CIT 961/4885 |
| US-20230330074-A1 | COMPOUNDS AND METHODS FOR TREATING SPASTICITY | SMN1; SMN2, MUSK, GAB1 | AAK1 62/4885MKNK1 545/4885CIT 2950/4885 |
| US-20210277001-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | AAK1 1/4885MKNK1 37/4885CIT 961/4885 |
| US-20220054464-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | EIF2AK2, SARS1, MAVS | AAK1 147/4885MKNK1 909/4885CIT 4154/4885 |
| US-20170183340-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | AAK1 1/4885MKNK1 37/4885CIT 961/4885 |
| US-11730723-B2 | Compounds and methods for treating viral infections | EIF2AK2, SARS1, MAVS | AAK1 147/4885MKNK1 909/4885CIT 4154/4885 |
| US-20180346440-A1 | BIARYL KINASE INHIBITORS | AAK1, CAMKK1, CAMKK2 | AAK1 1/4885MKNK1 46/4885CIT 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.